Stanford Researchers Uncover Novel Molecule BRP, Offering Potential for Semaglutide-Like Weight Loss Without Major Side Effects

Stanford Medicine researchers have identified a naturally occurring molecule, dubbed BRP, that shows promise in suppressing appetite and reducing body weight in animal models, mirroring the effects of semaglutide, the active ingredient in blockbuster drugs like Ozempic and Wegovy. Crucially, early findings suggest BRP may circumvent several challenging side effects commonly associated with existing GLP-1 receptor agonists, including nausea, constipation, and significant muscle loss. This groundbreaking discovery, heavily reliant on advanced artificial intelligence, was detailed in a study published on March 5 in the prestigious journal Nature, igniting cautious optimism within the medical and pharmaceutical communities for a new era of obesity treatment.

A New Pathway to Appetite Control: Precision Over Pervasiveness

The molecule BRP operates through a distinct yet related metabolic pathway compared to semaglutide. While both aim to regulate appetite and energy balance, BRP activates a separate, more specific group of neurons primarily within the brain’s hypothalamus. This critical distinction underpins its potential for a more targeted approach to weight management. Semaglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist, targets receptors found widely across the body—in the brain, gut, pancreas, and other tissues. This broad distribution contributes to its widespread physiological effects, such as slowing gastric emptying, which can lead to nausea and constipation, and influencing blood sugar levels.

In contrast, BRP appears to exert its primary influence specifically within the hypothalamus. This small but immensely powerful region, nestled deep within the brain, acts as the central command center for vital functions including hunger, satiety, body temperature regulation, hormone activity, and overall energy expenditure. Dr. Katrin Svensson, an assistant professor of pathology at Stanford Medicine and senior author of the research, elaborated on this specificity: "The receptors targeted by semaglutide are found in the brain but also in the gut, pancreas and other tissues. That’s why Ozempic has widespread effects including slowing the movement of food through the digestive tract and lowering blood sugar levels. In contrast, BRP appears to act specifically in the hypothalamus, which controls appetite and metabolism." This targeted action implies BRP could modulate appetite without triggering the cascade of systemic effects observed with broader-acting agents, potentially offering a therapeutic profile with fewer adverse reactions. The promise of this targeted mechanism is significant enough that Dr. Svensson has co-founded a company, Merrifield Therapeutics, with plans to initiate human clinical trials of BRP in the near future, marking a pivotal step toward translating these animal findings into human benefit. Senior research scientist Dr. Laetitia Coassolo served as the lead author of the study, contributing significantly to the intricate experimental design and execution.

The Dawn of AI-Driven Peptide Discovery: Unearthing Hidden Hormones

The identification of BRP represents a triumph of modern scientific methodology, particularly the integration of artificial intelligence into biological research. For decades, the search for novel therapeutic peptides has been a laborious and often serendipitous endeavor. Peptides, small chains of amino acids, often act as crucial signaling molecules or hormones, influencing complex biological processes throughout the body. Many of these biologically active peptides originate from larger, inactive precursor molecules known as prohormones. Enzymes cleave these prohormones into smaller fragments, some of which then become functional peptides.

The challenge lies in the sheer complexity of this process. A single prohormone can be cut in numerous ways, yielding a vast array of possible peptide fragments. Identifying the few genuine peptide hormones among a multitude of ordinary fragments, often created during routine protein processing and breakdown, is akin to finding a needle in a haystack. Traditional laboratory methods, while capable of isolating and identifying peptides, generate enormous datasets. Researchers might sift through hundreds of thousands of molecules, hoping to stumble upon the handful that possess meaningful biological effects. This resource-intensive and time-consuming process has historically limited the pace of discovery in this field.

The Stanford team specifically focused on an enzyme called prohormone convertase 1/3 (PC1/3), an enzyme known to cut prohormones at specific amino acid sequences. Intriguingly, PC1/3 has a well-established genetic link to human obesity, suggesting its involvement in metabolic regulation. One prominent peptide produced through the action of PC1/3 is glucagon-like peptide 1 (GLP-1), a key regulator of hunger and blood sugar. Semaglutide, by mimicking GLP-1, leverages this established pathway. The researchers hypothesized that if PC1/3 produced GLP-1, it might also produce other undiscovered peptides that influence energy balance and appetite, lying hidden within the vast biological data. This pivotal insight led them to turn to artificial intelligence for an unprecedented search.

Peptide Predictor: A Computational Leap Forward

Rather than relying on the arduous manual extraction of proteins and peptides from tissues and subsequent identification through techniques like mass spectrometry, the Stanford team developed a sophisticated computer algorithm named "Peptide Predictor." This innovative program was designed to systematically scan all 20,000 human protein-coding genes. Its primary task was to identify potential cleavage sites—specific amino acid sequences where prohormone convertases, particularly PC1/3, are known to cut proteins.

The algorithm’s power lay in its ability to rapidly filter and prioritize. The researchers further refined their search by concentrating on genes that produce proteins secreted outside the cell, a common characteristic of hormones, and which contained at least four possible cleavage sites. This meticulous process dramatically reduced the investigative field from an astronomical number of possibilities to a much more manageable group of 373 prohormones. "The algorithm was absolutely key to our findings," Dr. Svensson emphasized, highlighting the indispensable role of AI in accelerating discovery.

From these 373 prohormones, Peptide Predictor estimated that PC1/3 could generate 2,683 distinct peptides. Drs. Coassolo and Svensson then strategically narrowed their focus, prioritizing sequences that appeared most likely to interact with or affect the brain, given their interest in appetite control. This rigorous computational screening culminated in the selection of 100 candidate peptides for laboratory testing, a list that importantly included the well-known GLP-1 as a positive control.

From Lab Bench to Potent Peptide: The Unveiling of BRP

The selected 100 peptides were then subjected to in vitro testing, where their ability to stimulate neuron-like cells grown in the laboratory was assessed. As anticipated, GLP-1 robustly activated these neuronal cells, boosting their activity to three times the level observed in untreated control cells, confirming the validity of the experimental setup. However, the true breakthrough came with the observation of a much smaller peptide that elicited an even more dramatic response. This tiny molecule, composed of merely 12 amino acids, astonishingly increased neuronal activity tenfold compared with controls. Its potent effect, despite its minuscule size relative to most full-sized proteins, immediately signaled its significance.

The researchers named this exceptionally powerful peptide BRP, short for BRINP2-related-peptide, derived from its parent prohormone, BPM/retinoic acid inducible neural specific 2 (BRINP2). This discovery represented a significant validation of their AI-driven approach, demonstrating its capacity to unearth novel, highly active biological molecules previously overlooked by conventional methods.

Pre-Clinical Validation: Remarkable Results in Animal Models

With the identification of BRP, the team moved to in vivo studies to assess its efficacy and safety in living organisms. They first tested BRP in lean mice and minipigs, the latter being particularly valuable models due to their metabolic and eating patterns more closely mirroring those of humans than rodents. A single intramuscular injection of BRP administered before feeding resulted in a profound reduction in food intake, by as much as 50% during the subsequent hour, in both species. This immediate and significant impact on feeding behavior was a powerful indicator of BRP’s appetite-suppressing capabilities.

To evaluate its long-term effects on weight and metabolic health, the researchers conducted a 14-day study where obese mice received daily BRP injections. The results were compelling: treated animals lost an average of 3 grams, with nearly the entire reduction attributed to body fat. In stark contrast, mice in the control group, which did not receive BRP, gained approximately 3 grams over the same two-week period. Beyond weight loss, the treated mice also exhibited improved glucose and insulin tolerance. These critical metabolic markers indicate the body’s enhanced ability to regulate blood sugar levels and respond effectively to insulin, the hormone responsible for facilitating glucose uptake into cells. Improved glucose and insulin tolerance are key indicators of better metabolic health and reduced risk for conditions like Type 2 diabetes, adding another layer of therapeutic potential to BRP.

A Cleaner Profile: Avoiding Common Side Effects

Perhaps one of the most exciting aspects of BRP’s pre-clinical profile is its apparent avoidance of many common and bothersome side effects associated with existing weight-loss medications, particularly GLP-1 receptor agonists. Behavioral testing in the treated animals revealed no meaningful differences compared to untreated controls in terms of movement patterns, water consumption, anxiety-like behaviors, or crucially, fecal production. The stability in fecal production is particularly noteworthy, as semaglutide and similar drugs are known to slow digestion, often leading to constipation, a frequent complaint among users.

Furthermore, the researchers did not observe any signs of nausea-related responses in the animals, nor did they detect major muscle loss—a concerning side effect that has gained attention with some existing weight-loss treatments, where a significant portion of the weight reduction can come from lean body mass rather than just fat. These findings strongly suggest that BRP’s targeted action in the hypothalamus allows it to influence appetite and metabolism without triggering the widespread gastrointestinal or systemic adverse effects seen with less specific agents. Additional measurements of brain activity and body function further reinforced that BRP operates through metabolic and neuronal pathways distinct from those activated by GLP-1 or semaglutide, underscoring its unique mechanism of action. While these results are currently limited to animal studies, they paint a promising picture of a potential weight-loss therapy with a significantly improved side effect profile.

The Road Ahead: Challenges and Prospects for Human Trials

Despite the highly encouraging animal study results, the journey from laboratory discovery to a widely available human therapeutic is long and fraught with challenges. The Stanford team is now focused on several key areas of investigation before BRP can progress to human clinical trials. A primary objective is to identify the specific cell-surface receptors that BRP binds to. Receptors are molecular structures on cell surfaces that act as docking stations for hormones, drugs, and other chemical messengers. Pinpointing BRP’s precise receptor will be instrumental in fully elucidating how this peptide modulates appetite and metabolism at a molecular level. Understanding this intricate binding mechanism is crucial for further drug development and optimization.

Another critical challenge lies in the inherent nature of small peptides: they are often rapidly broken down in the body, which can significantly limit the duration of their effects. For BRP to be a practical and effective therapeutic for humans, its duration of action needs to be extended. The researchers are actively exploring strategies to enhance BRP’s stability and longevity in vivo, which could involve chemical modifications to the peptide itself or novel delivery systems. Achieving a practical dosing schedule—perhaps once-daily, weekly, or even less frequent administration—will be essential for patient adherence and widespread adoption, should BRP prove effective in humans.

Dr. Svensson acknowledged the decades-long struggle to find truly effective and well-tolerated drugs for obesity: "The lack of effective drugs to treat obesity in humans has been a problem for decades. Nothing we’ve tested before has compared to semaglutide’s ability to decrease appetite and body weight. We are very eager to learn if it is safe and effective in humans." This sentiment underscores the profound impact semaglutide has had on the obesity treatment landscape, and the hope that BRP might build upon that success with an even better therapeutic profile.

Broader Implications for the Global Health Crisis

The global obesity epidemic remains one of the most pressing public health challenges of the 21st century, contributing significantly to a myriad of chronic diseases including type 2 diabetes, cardiovascular disease, certain cancers, and musculoskeletal disorders. The current arsenal of anti-obesity medications, while expanding, still leaves considerable room for improvement in terms of efficacy, tolerability, and accessibility. Semaglutide and similar GLP-1 agonists have revolutionized the treatment of obesity, offering unprecedented weight loss results, but their side effect profiles, particularly gastrointestinal issues and concerns about muscle loss, can limit patient adherence and overall benefit.

The discovery of BRP, with its targeted action and apparent reduction in common side effects, represents a significant step forward in the quest for safer and more precise obesity treatments. If BRP proves safe and effective in human trials, its implications could be far-reaching. It could offer a viable alternative for patients who experience intolerable side effects from existing GLP-1 agonists, or it could potentially be used in combination therapies to achieve even greater weight loss with fewer adverse events. Pharmaceutical companies, keenly aware of the massive market for weight-loss drugs, will undoubtedly be watching Merrifield Therapeutics’ clinical trial progress with intense interest. This research also highlights the transformative potential of artificial intelligence in accelerating drug discovery, opening new avenues for identifying novel therapeutic targets and molecules across various disease areas.

This pioneering work was a collaborative effort, with significant contributions from researchers at the University of California, Berkeley; the University of Minnesota; and the University of British Columbia. Financial support for this extensive study was provided by multiple prestigious organizations, including the National Institutes of Health (through grants R01DK125260, P30DK116074, K99AR081618, and GM113854), the SPARK Translational Research Program at Stanford, Stanford Bio-X, the Stanford Maternal and Child Health Research Institute, the American Heart Association, a Stanford Medicine Dean’s Fellowship Award, the Carlsberg Foundation, and the Wu Tsai Human Performance Alliance. In the interest of full transparency, it is noted that Dr. Svensson and Dr. Coassolo are inventors on patents related to BRP peptides for metabolic disorders, and Dr. Svensson is a co-founder of Merrifield Therapeutics, the company poised to advance BRP into human clinical trials.

As the scientific community awaits the initiation and results of human trials, the discovery of BRP stands as a testament to the power of interdisciplinary research, cutting-edge technology, and persistent inquiry in addressing some of the most complex health challenges of our time. The prospect of a highly effective, well-tolerated, and precisely targeted therapy for obesity moves a step closer to reality.